Health
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
FOSTER CITY, Calif., May 21, 2026--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":280,"url":"https://media.zenfs.com/en/business-wire.com/b0aa843b0556d3a4c7c802721ef5006d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Xg8Kk_9b5COr8eYZgyhDdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MA--/https://media.zenfs.com/en/business-wire.com/b0aa843b0556d3a4c7c802721ef5006d","width":480,"height":280},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/72WZVxAqxpyYmmeSyqGjeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM3Mw--/https://media.zenfs.com/en/business-wire.com/b0aa843b0556d3a4c7c802721ef5006d","width":480,"height":280}},"lazy":false},{"type":"text","content":"- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC)","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"- Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV)","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"- Additional presentations highlight long-term outcomes and real-world experience with LIVMARLI® (maralixibat) in progressive familial intrahepatic cholestasis (PFIC)","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"FOSTER CITY, Calif., May 21, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present new data at the European Association for the Study of the Liver (EASL) International Liver Congress 2026, taking place May 27-30, 2026, in Barcelona, Spain.","length":321,"tagName":"p"},{"type":"text","content":"Presentations span Mirum’s rare liver disease programs, including late-breaking data from the company’s Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV, alongside data featuring its established therapy, LIVMARLI® (maralixibat) in PFIC. Together, these data highlight the breadth of Mirum’s rare liver disease portfolio.","length":361,"tagName":"p"},{"type":"text","content":""We’ve built our rare liver disease business by staying close to patients and focusing on the needs and outcomes that most affect their daily lives," said Chris Pe...